Vertex Pharmaceuticals Incorporated (BVMF:VRTX34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 715.07B +31.7% |
| Revenue (ttm) | 65.21B +10.2% |
| Net Income | 22.82B +21.1% |
| EPS | 89.02 +22.1% |
| Shares Out | n/a |
| PE Ratio | 31.33 |
| Forward PE | 26.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102 |
| Open | 88.73 |
| Previous Close | 88.73 |
| Day's Range | 88.10 - 88.73 |
| 52-Week Range | 62.20 - 89.01 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 3, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
News
Vertex to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investo...
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
BofA analysts added Vertex Pharmaceuticals (VRTX) to the firm’s “US 1 List.” The list represents BofA’s best investment ideas.
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $672 from $605 and keeps a Buy rating on the shares after competitor Sionna Therapeutics (SION) reported that its…
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
Shares of American biotech company Vertex Pharmaceuticals ($VRTX) jumped about 7% on Monday after its top rival Sionna Therapeutics ($SION) reported the failure of a trial of its new cystic…
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $565 from $560 and keeps a Buy rating on the shares.
Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $617 from $615 and keeps an Overweight rating on the shares. The firm continues to like the share setup…
Vertex Pharmaceuticals price target raised to $605 from $600 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $605 from $600 and keeps a Buy rating on the shares. FY26 revenue guidance was raised…
Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $595 from $590 and keeps an Overweight rating on the shares. Vertex delivered a strong Q2 with broad…
Vertex Pharmaceuticals price target raised to $550 from $525 at TD Cowen
TD Cowen analyst Phil Nadeau raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $525 and keeps a Buy rating on the shares. The firm updated its…
Vertex Pharmaceuticals price target raised to $442 from $430 at Canaccord
Canaccord raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $442 from $430 and keeps a Hold rating on the shares. The firm noted they reported a top line…
Vertex Pharmaceuticals price target raised to $500 from $466 at Stifel
Stifel raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $500 from $466 and keeps a Hold rating on the shares. The cystic fibrosis business continues to do well…
Vertex Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 revenue rose 12% year-over-year to $3.3B, led by CF, CASGEVY, and JOURNAVX growth. The company raised full-year guidance, advanced its pipeline, and announced the $8.8B Crinetics acquisition, adding a fifth commercial pillar in rare endocrine diseases.
Vertex Pharmaceuticals Earnings release: Q2 2026
Vertex Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Vertex Pharmaceuticals Slides: Q2 2026
Vertex Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.
Vertex Pharmaceuticals Quarterly report: Q2 2026
Vertex Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
Vertex Pharmaceuticals reports Q2 adjusted EPS $4.73, consensus $4.75
Reports Q2 revenue $3.33B, consensus $3.22B. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, b...
Vertex Pharmaceuticals ups FY26 revenue view to $13.1B-$13.2B, consensus $13.05B
Vertex raised its full year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously. Embedded in this guidance are expectations for continued…
Vertex raises annual revenue forecast on cystic fibrosis drugs strength
Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments.
Vertex Reports Second Quarter 2026 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 rev...
AbCellera announces collaboration with Vertex Pharmaceuticals
AbCellera (ABCL) announced a collaboration with Vertex Pharmaceuticals Incorporated (VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers, TCEs, for autoimmune dise...
Vertex Pharmaceuticals price target raised to $585 from $545 at UBS
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $585 from $545 and keeps a Buy rating on the shares.
How to Ride the $2.6 Trillion Merger Boom With High-Growth Stocks
More mergers among brand-name consumer companies seem likely—following a record $2.6 trillion worth of transactions announced in the first half of 2026.
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The comp...
Crinetics shares surge after Vertex agrees to $10B cash buyout
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-...